Financial Performance - Total net sales for the three months ended March 31, 2023, increased by $5.3 million, or 31%, compared to the same period in 2022[190] - The net loss for the three months ended March 31, 2023, was $1.9 million, compared to a net loss of $7.7 million for the same period in 2022[190] - Basic and diluted loss per common share for the three months ended March 31, 2023, was $0.03, an improvement from $0.11 in the same period in 2022[190] - Gross profit for the consumer products segment increased to $11,229,000, a 16% rise from $9,685,000 in the same period of 2022[194] - Total gross profit reached $13,518,000, reflecting a 28% increase compared to $10,532,000 in the prior year[194] Sales and Revenue - Ingredient sales for the same period grew by approximately $2.7 million, representing a 189% increase, driven by demand for the Niagen® ingredient[191] - The cost of sales as a percentage of net sales for the ingredients segment declined by 5% for the three months ended March 31, 2023, attributed to economies of scale from higher sales volumes[193] Expenses - Selling and marketing expenses for consumer products decreased by $0.3 million, or 4%, due to a strategic shift in marketing approach[196] - Total selling and marketing expenses for analytical reference standards and services segment decreased by approximately $56,000, or 40%[197] - Research and development expenses increased due to inflationary pressures, including wage inflation and higher share-based compensation[198] - General and administrative expenses decreased by 28% to $6,419,000 from $8,949,000 in the same period of 2022[199] Cash Flow and Financial Position - As of March 31, 2023, the company had cash and cash equivalents of $23.1 million, including $152,000 of restricted cash[201] - Net cash provided by operating activities was approximately $2.8 million for the three months ended March 31, 2023, compared to a net cash outflow of $7.2 million in the same period of 2022[202] - The company incurred aggregate losses of approximately $187.4 million since inception, primarily due to operational development and intellectual property protection expenses[200] - Purchase obligations related to inventory commitments totaled $15.5 million, with future minimum lease obligations of $4.7 million[201] Research and Development - The company has over 475 published human clinical studies related to NAD+ and its impact on health, indicating a strong research foundation[137] - The company has established more than 250 research partnerships through its ChromaDex External Research Program (CERP™) with leading institutions globally[185] Joint Ventures and Tax Credits - The company has a joint venture to commercialize Tru Niagen® in Mainland China, holding an 89% equity interest in the venture[156] - The company recorded an aggregate benefit of approximately $2.1 million from the Employee Retention Tax Credit for eligible quarters in 2020 and 2021[154] Future Expectations - The company expects to recognize approximately $7.0 million in share-based compensation expense for unvested options and $1.9 million for unvested restricted stock units in future periods[147]

to safely elevate NAD+ levels and the only patented form of nicotinamide riboside (Niagen®) available in the world. Our History (2000-Present) Partnered with Partnered with Launched healthcare practitioner business Announced supply agreement with TRU NIAGEN Singapore New Zealand Commercialized Niagen® (trademarked NR) 2003 2016 2000 2002 2017 2018 2019 2020 2021 2022 Launched Tru Niagen® Beauty with Partnered with Tru Niagen® is the most efficient way to safely elevate NAD+ (1) Related to Nicotinamide Ribos ...

ChromaDex Corporation (NASDAQ:CDXC) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors, Agency IR Counsel Rob Fried – Chief Executive Officer Brianna Gerber – Chief Financial Officer Andrew Shao – Senior Vice President-Scientific and Regulatory Affairs Conference Call Participants Mitch Pinheiro – Sturdivant Jeff Van Sinderen – B. Riley Ram Selvaraju – H.C. Wainwright Destiny Hance – Ladenburg Thalmann Sean McGowan – Roth MKM Bill Dezellem – Tieton ...

Financial Performance - Total net sales for ChromaDex increased by 7% to $72.05 million in 2022, compared to $67.45 million in 2021[403] - Consumer Products segment sales rose by 6% to $60.11 million in 2022, up from $56.71 million in 2021[403] - Ingredients segment sales increased by 18% to $8.74 million in 2022, compared to $7.41 million in 2021[403] - Total gross profit increased from $16.1 million in 2018 to $42.8 million in 2022, representing a 22% compound annual growth rate[406] - Gross profit for fiscal year 2022 increased by $1.3 million, or 3%, compared to 2021, with a gross margin percentage of 59.4%, down 210 basis points from 2021[406] Costs and Expenses - Total cost of sales grew by 13% to $29.25 million in 2022, up from $25.96 million in 2021, with a total cost of sales as a percentage of net sales increasing from 38% to 41%[405] - General and administrative expenses decreased by 22% from $36.4 million in 2021 to $28.3 million in 2022[410] - Losses from operations for the year ended December 31, 2022, were approximately $16.5 million, primarily due to expenses related to operational expansion and legal expenditures[417] Cash Flow - Net cash used in operating activities was approximately $15.1 million in 2022, a decrease from $24.2 million in 2021, primarily due to an improvement in net loss[412] - Net cash provided by financing activities decreased to approximately $7.7 million in 2022 from $36.1 million in 2021, attributed to reduced proceeds from common stock issuance[413] Revenue and Income - The company recognized approximately $2.1 million in Other income from the Employee Retention Tax Credit (ERTC) during 2022[211] - Revenue from bill-and-hold arrangements was $1.7 million for the year ended December 31, 2022, with no revenue recorded for 2021[424] Inventory and Commitments - ChromaDex has a commitment to purchase approximately $18.0 million of inventory from W.R. Grace & Co. during fiscal year 2023[209] Regulatory and Market Challenges - The company faces challenges from inflation in labor, raw materials, and transportation costs, which may impact margins and production volumes[213] - The ongoing COVID-19 pandemic continues to create uncertainty and disruption, affecting workforce and operations[210] - ChromaDex is subject to various regulations regarding dietary supplements, which may impact product marketing and approvals[198] Balance Sheet Items - Deferred revenue balances were $4.0 million as of December 31, 2022, down from $4.3 million in 2021[423] - Accounts payable as of December 31, 2022, was $9.7 million, a decrease from approximately $10.4 million in 2021[416] Dividends - The company has not declared or paid any cash dividends on its common stock, intending to retain earnings for operational use[420]

ChromaDex Corporation (NASDAQ:CDXC) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tom Shumaker - Investor Relations Robert Fried - Chief Executive Officer Brianna Gerber - Interim Chief Financial Officer Conference Call Participants Jeff Cohen - Ladenburg Thalmann Sean McGowan - ROTH Capital Jeff Van Sinderen - B. Riley Mitchell Pinheiro - Sturdivant & Company Brian Nagel - Oppenheimer Operator Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|---------------------------------------------- ...

ChromaDex Corporation (NASDAQ:CDXC) Q2 2022 Results Conference Call August 10, 2022 4:30 AM ET Company Participants Heather Van Blarcom - Senior Vice President of Legal and Corporate Secretary Robert Fried - Chief Executive Officer Kevin Farr - Chief Financial Officer Brianna Gerber - Vice President of Finance and Investor Relations Conference Call Participants Brian Nagel - Oppenheimer Mitchell Pinheiro - Sturdivant Raghuram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital Jeffrey Cohen - Ladenburg ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|--------------------------------------------------- ...

| --- | --- | |--------------------------|-------| | | | | ChromaDex | | | | | | | | | | | | Earnings Conference Call | | | | | | First Quarter 2022 | | Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | May 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securitie ...

ChromaDex Corporation (NASDAQ:CDXC) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Rob Fried – Chief Executive Officer Kevin Farr – Chief Financial Officer Brianna Gerber – Vice President of Finance, Investor Relation Frank Jaksch – Co-Founder and Executive Chairman Conference Call Participants Brian W. Nagel – Oppenheimer & Co. Mitchell Pinheiro – Sturdivant & Co. Sean McGowan – ROTH Capital Partners Bill Dezellem – Tieton Capital Management Operator Ladies and gentlemen, tha ...